September 13, 2017 / 5:25 AM / 3 months ago

BRIEF-Novartis says Cosentyx sustains skin clearance at 5 years

Sept 13 (Reuters) - Novartis

* Says cosentyx shows sustained skin clearance rates at 5 years in phaseiii study in psoriasis

* Novartis says 5-year data from a phase iii study reinforce cosentyx's long term skin clearance and safety Source text for Eikon: [here ] Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below